Chemotherapy compliance in patients with osteosarcoma

Pediatric Blood and Cancer

Volumn 60, Issue 1, 2013, Pages 41-44

  Bajpai, Jyoti ^a   Puri, Ajay ^a   Shah, Kajal ^a   Susan, Deepa ^a   Jambhekar, Nirmala ^a   Rekhi, Bharat ^a   Desai, Saral ^a   Gulia, Ashish ^a   Gupta, Sudeep ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Chemotherapy; Compliance; Osteosarcoma

Indexed keywords

ALBUMIN; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; LACTATE DEHYDROGENASE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BONE MARROW SUPPRESSION; CANCER PAIN; CHILD; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFECT; EDUCATIONAL STATUS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 84870219145     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24155     Document Type: Article

References (15)

1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115: 1531-1543.
2. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10: 5-15.
3. Bielack S, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
4. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-Year experience in 789 patients treated at a single institution. Cancer 2006; 106: 1154-1161.
5. Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-2177.
6. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977; 101: 14-18.
7. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-1230.
8. Lewis C, Linet MS, Abeloff MD. Compliance with cancer therapy by patients and physicians. Am J Med 1983; 74: 673-678.
9. Olivotto A, Coldman AJ, Hislop TG, et al. Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol 1997; 15: 216-222.
10. Balasubramanian SP, Murrow S, Holt S, et al. Audit of compliance to adjuvant chemotherapy and radiotherapy guidelines in breast cancer in a cancer network. Breast 2003; 12: 136-141.
11. Ray-Coquard I, Philip T, Lehmann M, et al. Impact of a clinical guidelines program for breastand colon cancer in a French cancer center. JAMA 1997; 278: 1591-1595.
12. Guadagnoli E, Shapiro CL, Weeks JC, et al. The quality of care for treatment of early stage breast carcinoma. Is it consistent with national guidelines? Cancer 1998; 83: 302-309.
13. Smith TJ, Hillner BE. Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. J Clin Oncol 2001; 19: 2886-2897.
14. Borras JM, SanchezHernandez A, Navarro M, et al. Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: A randomized controlled trial. BMJ 2001; 322: 1-5.
15. Alam N, Shepherd FA, Winton T. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and Intergroup Trial JBR.10 and a review of the literature. Lung Cancer 2005; 47: 385-394.